ABSTRACT
BACKGROUND AND PURPOSE: A recent paradigm shift in proarrhythmic risk assessment suggests that the integration of clinical, non-clinical, and computational evidence can be used to reach a comprehensive understanding of the proarrhythmic potential of drug candidates. While current computational methodologies focus on predicting the incidence of proarrhythmic events after drug administration, the objective of this study is to predict concentration-response relationships of QTc as a clinical endpoint. EXPERIMENTAL APPROACH: Full heart computational models reproducing human cardiac populations were created to predict the concentration-response relationship of changes in the QT interval as recommended for clinical trials. The concentration-response relationship of the QT-interval prolongation obtained from the computational cardiac population was compared against the relationship from clinical trial data for a set of well-characterized compounds: moxifloxacin, dofetilide, verapamil, and ondansetron. KEY RESULTS: Computationally derived concentration-response relationships of QT interval changes for three of the four drugs had slopes within the confidence interval of clinical trials (dofetilide, moxifloxacin and verapamil) when compared to placebo-corrected concentration-ΔQT and concentration-ΔQT regressions. Moxifloxacin showed a higher intercept, outside the confidence interval of the clinical data, demonstrating that in this example, the standard linear regression does not appropriately capture the concentration-response results at very low concentrations. The concentrations corresponding to a mean QTc prolongation of 10 ms were consistently lower in the computational model than in clinical data. The critical concentration varied within an approximate ratio of 0.5 (moxifloxacin and ondansetron) and 1 times (dofetilide, verapamil) the critical concentration observed in human clinical trials. Notably, no other in silico methodology can approximate the human critical concentration values for a QT interval prolongation of 10 ms. CONCLUSION AND IMPLICATIONS: Computational concentration-response modelling of a virtual population of high-resolution, 3-dimensional cardiac models can provide comparable information to clinical data and could be used to complement pre-clinical and clinical safety packages. It provides access to an unlimited exposure range to support trial design and can improve the understanding of pre-clinical-clinical translation.
Subject(s)
Fluoroquinolones , Long QT Syndrome , Phenethylamines , Sulfonamides , Humans , Dose-Response Relationship, Drug , Electrocardiography , Fluoroquinolones/adverse effects , Heart Rate , Long QT Syndrome/chemically induced , Long QT Syndrome/drug therapy , Moxifloxacin/therapeutic use , Ondansetron/therapeutic use , VerapamilABSTRACT
It was found that Argentatins A and B triterpenoids make up approximately 20-30 % of the waste resin produced from the industrial processes to isolate rubber from P. argentatum. We have developed an efficient protocol for synthesizing cycloartane-16ß-ol derivatives by opening the oxepane ring of argentatin B acetate (2) with BF3-OEt2. Although three new cycloartenol derivatives showed high cytotoxicity against PC-3 and HCT-15 cancer cell lines, nevertheless, the best results were obtained for (16ß,24R) -(16,24-epoxy-cycloartan-2(1H)-ylidene) acetate (14), compound with intact oxepane ring. These results indicate that the substituents in the argentatin nucleus and a side chain account for the cytotoxic activity. However, according to the selectivity index (SI), 14 did not show selectivity activity to cancer cell lines over the HaCat noncancerous cell line. The compound 3ß,16ß-Dihydroxy-cycloartan-24-one (5), synthesized by oxepane opening, demonstrated high cytotoxic activity to cancer cell lines and showed a remarkable selectivity to cancer cell lines over the noncancerous ones. These results suggest that 5 could lead to the development of new anticancer compounds.
Subject(s)
Antineoplastic Agents , Drug Screening Assays, Antitumor , Humans , Cell Line, Tumor , Antineoplastic Agents/pharmacology , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Structure-Activity Relationship , Cell Proliferation/drug effects , Triterpenes/pharmacology , Triterpenes/chemistry , Triterpenes/chemical synthesis , Tetrazoles/pharmacology , Tetrazoles/chemical synthesis , Tetrazoles/chemistry , Molecular Structure , Dose-Response Relationship, Drug , Cell Survival/drug effectsABSTRACT
TAVR has emerged as a standard approach for treating severe aortic stenosis patients. However, it is associated with several clinical complications, including subclinical leaflet thrombosis characterized by Hypoattenuated Leaflet Thickening (HALT). A rigorous analysis of TAVR device thrombogenicity considering anatomical variations is essential for estimating this risk. Clinicians use the Sinotubular Junction (STJ) diameter for TAVR sizing, but there is a paucity of research on its influence on TAVR devices thrombogenicity. A Medtronic Evolut® TAVR device was deployed in three patient models with varying STJ diameters (26, 30, and 34 mm) to evaluate its impact on post-deployment hemodynamics and thrombogenicity, employing a novel computational framework combining prosthesis deployment and fluid-structure interaction analysis. The 30 mm STJ patient case exhibited the best hemodynamic performance: 5.94 mmHg mean transvalvular pressure gradient (TPG), 2.64 cm2 mean geometric orifice area (GOA), and the lowest mean residence time (TR)-indicating a reduced thrombogenic risk; 26 mm STJ exhibited a 10 % reduction in GOA and a 35% increase in mean TPG compared to the 30 mm STJ; 34 mm STJ depicted hemodynamics comparable to the 30 mm STJ, but with a 6% increase in TR and elevated platelet stress accumulation. A smaller STJ size impairs adequate expansion of the TAVR stent, which may lead to suboptimal hemodynamic performance. Conversely, a larger STJ size marginally enhances the hemodynamic performance but increases the risk of TAVR leaflet thrombosis. Such analysis can aid pre-procedural planning and minimize the risk of TAVR leaflet thrombosis.
Subject(s)
Aortic Valve Stenosis , Heart Valve Prosthesis , Thrombosis , Transcatheter Aortic Valve Replacement , Humans , Aortic Valve/surgery , Transcatheter Aortic Valve Replacement/adverse effects , Aorta, Thoracic , Hemodynamics , Thrombosis/etiology , Aortic Valve Stenosis/surgery , Heart Valve Prosthesis/adverse effects , Treatment OutcomeABSTRACT
Abstract Some species of the Clusia genus have been shown to have important biomedical properties, including the ability to inhibit tumor growth in vitro and the usefulness for skin care. In this study, we examined the cytotoxic effect of hexane, ethyl acetate and methanol extracts from Clusia latipes Planch. & Triana, Clusiaceae, leaves on survival of human prostate cancer cells (PC-3), colon cancer cells (RKO), astrocytoma cells (D-384), and breast cancer cells (MCF-7). The ethyl acetate extract displayed the most substantial cytotoxic effect. However, using a Comet assay, we observed that the hexane extract induced a genotoxic effect (DNA damage) on human lymphocytes in an in vitro model. Chromatographic purification of the C. latipes hexane extract led to the isolation and identification of friedelin, friedolan-3-ol, and hesperidin as active cytotoxic compounds in hexane extract, while β-amyrine was identified as an active cytotoxic compound in the ethyl acetate extract of C. latipes, thereby supporting further studies of the molecular mechanisms underlying the effect of these secondary metabolites on cancer cell survival.
ABSTRACT
Two glucosinolates (glucoraphasatin and glucoraphanin) and their degradation products (raphasatin and sulforaphane) are secondary metabolites which have shown antioxidant properties and inhibitory properties against the hepatic cholesterol; these effects are very important for the prevention of cholesterol gallstones because in their pathophysiology there is an imbalance in the transport and secretion of cholesterol. These effects produce oxygen reactive species formation, which damages the hepatic and biliary tissues. Cholesterol gallstones are a public health problem; their pharmacological treatment is very limited and the invasive surgical treatment for symptomatic gallstones is the cholecystectomy. Current research focuses on the search for preventive treatments, as there are many risk factors associated with the development of gallstones; therefore, a natural therapeutic alternative may be the use of these glucosinolates and their degradation products.
Dos glucosinolatos (glucorafasatina y glucorafanina) y sus productos de degradación (rafasatina y sulforafano) son metabolitos secundarios que han demostrado propiedades antioxidantes y propiedades inhibidoras contra el colesterol hepático; estos efectos son muy importantes para la prevención de cálculos biliares de colesterol porque en su fisiopatología existe un desajuste en el transporte y secreción del colesterol. Estos efectos producen la formación de especies reactivas de oxígeno, que dañan los tejidos hepático y biliar. Los cálculos biliares de colesterol son un problema de salud pública, su terapia farmacológica es muy limitada y el tratamiento quirúrgico invasivo para cálculos biliares sintomáticos es la colecistectomía. Las investigaciones actuales están orientadas a la búsqueda de tratamientos preventivos, porque hay muchos factores de riesgo asociados al desarrollo de cálculos biliares; por lo tanto, una alternativa terapéutica natural podría ser el uso de estos glucosinolatos, así como sus productos de degradación.